Video

So, I think this new EULAR/PreS recommendations for diagnosis management of Still’s disease have really opened a new era in this disease. We have now a common name. The disease is again, Still’s disease.

We have now common treatment targets and goals and the ultimate goal is to have a drug-free remission, which sounds very ambitious, but it's not over ambitious, so it is achievable. We agreed clearly that the systemic manifestations of disease are sometimes life-threatening, especially macrophage activation syndrome should be taken into account from the beginning on because in most of the cases it is something which starts within the first weeks and months after disease onset, but it can also appear later. So, we have to be suspicious and careful (Feist, 2024).

And we can maybe avoid a worse outcome if we diagnose early and start with the treatment early on in the window of opportunity, which does exist for Still’s disease. And I think what we can say is that targeted approaches by inhibiting the Interleukin-1 and 6 signalling pathway are preferable in the management of patients with Still’s disease and helps us also to avoid unnecessary exposure to glucocorticoids and helps us also of course to avoid long-term side effects of glucocorticoid treatment, which is very very important also not only for children but also for adults of course (Fautrel, 2024).